drug
abaloparatide
Marketedupdated 4mo agoby Radius Health Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying abaloparatide
- phase4Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
- phase4Abaloparatide Before Total Knee Arthroplasty
- phase4Supracondylar Distal Femur Fractures and Abaloparatide
- —Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
- phase1Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 3, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Jan 10, 2040method-of-use (U-3322)US 11255842
- Jan 10, 2040method-of-use (U-3322)US 11680942
- Apr 30, 2038formulationUS 10996208
- Apr 30, 2038formulationUS 11782041
- Apr 30, 2038formulationUS 11977067
- Apr 28, 2031method-of-use (U-2009)US 78037704.7y
- Apr 28, 2031method-of-use (U-3543)US RE494444.7y
- Nov 8, 2027formulationUS 81483331.2y
- Oct 3, 2027method-of-use (U-2009)US 87483821.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that